Physicochemical Properties
| Molecular Formula | C16H13CLN6S |
| Molecular Weight | 356.83 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Compound 10, also known as tubulin inhibitor 36, exhibits anti-proliferative effect against human tumor cell lines. The IC50 values are 0.039, 0.038, 0.022, 0.025, and 0.037 against HeLa, MCF7, U87 MG, T98G, HepG2, HCT8, and HT-29 cells, in that order. ,0.040,0.059 micrometers [1]. In HeLa, MCF7, and U87 MG cells, tubulin inhibitor 36 (Compound 10) (100 nM, 24 h, 48 h, and 72 h) can impede mitosis and cause apoptosis [1]. |
| Cell Assay |
Immunofluorescence[1] Cell Types: HeLa, MCF7, U87 MG cells Tested Concentrations: 100 nM Incubation Duration: 24 h Experimental Results: Arrested tubulin polymerization in HeLa, MCF7, and U87 MG cells. Cell Cycle Analysis[1] Cell Types: HeLa, MCF7, U87 MG cells Tested Concentrations: 100 nM Incubation Duration: 24 h, 48 h, 72 h Experimental Results: Induced remarkable mitotic arrest in 24 h of HeLa cells. Induced mitotic arrest in 24 h of MCF7 cells but lower cell death compared to HeLa cells Induced remarkable mitotic arrest in 24 h of U87 MG cells and severe cell death. Apoptosis Analysis[1] Cell Types: HeLa, MCF7, U87 MG cells Tested Concentrations: 100 nM Incubation Duration: 72 h Experimental Results: Induced nearly 73% of apoptosis in 72 h of HeLa cells and lower levels of MCF7 cells Induced lower cell death levels of MCF7 cells Displayed the highest cell death levels of d U87 MG cells |
| References | [1]. Gallego-Yerga L, et al. Novel Tetrazole Derivatives Targeting Tubulin Endowed with Antiproliferative Activity against Glioblastoma Cells. Int J Mol Sci. 2023 Jul 4;24(13):11093. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8025 mL | 14.0123 mL | 28.0245 mL | |
| 5 mM | 0.5605 mL | 2.8025 mL | 5.6049 mL | |
| 10 mM | 0.2802 mL | 1.4012 mL | 2.8025 mL |